13F Holdings
中文EN

MTRI InMed Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1728328 · Fiscal year ends 06/30

Financial factors as of 2025-12-31 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-6.7%
TTM net income YoY3.1%
TTM EPS YoY76.7%
Revenue 3-yr CAGR40.8%
Net income 3-yr CAGR—

Margins

Gross margin29.7%
Operating margin—
Net margin-170.1%
FCF margin—
EBITDA margin—

Returns

ROE-97.2%
ROA-77.8%
ROIC (approx.)—
Asset turnover0.46x

Leverage & solvency

Liabilities / assets14.3%
Debt / equity0.00x
Current ratio5.94x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.01x
Accruals ratio0.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-06-30FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30
Income statement
Revenue—$4.94M$4.60M$4.14M$1.09M
Cost of revenue—$3.24M$3.50M$2.73M$545,889
Gross profit—$1.71M$1.10M$1.40M$543,546
R&D expense$3.03M$2.82M$3.22M$3.73M$7.28M
SG&A expense$6.66M$5.41M$5.80M$5.85M$6.87M
Operating income———-$7.95M-$18.60M
Pretax income-$11.37M-$8.69M-$7.67M-$7.93M-$18.60M
Income tax——$7,100$13,100—
Net income-$12.56M-$8.16M-$7.68M-$7.95M-$18.60M
EBITDA———-$7.75M-$18.41M
EPS (basic)-3.12-8.36-20.14-3.25-33.17
EPS (diluted)-3.12-8.36-20.14-3.25-33.17
Weighted avg. shares (diluted)4.16M975,895381,0532.45M560,829
Balance sheet
Cash & equivalents$2.19M$10.74M$6.57M$8.91M$6.18M
Short-term investments$39,670$43,384$43,064$44,422$44,804
Receivables—$465,104$352,838$260,399$88,027
Inventory—$961,173$1.24M$1.62M$2.49M
Current assets$2.68M$12.87M$8.69M$11.33M$9.60M
PP&E, net$221,037$992,199$1.25M$723,426$904,252
Intangibles—$1.62M$1.78M$1.95M$2.11M
Total assets$3.03M$15.58M$11.82M$14.11M$12.79M
Current liabilities$1.96M$1.84M$1.97M$2.00M$3.32M
Total liabilities$1.96M$2.15M$2.62M$2.02M$3.71M
Shareholders' equity$1.08M$13.43M$9.21M$12.09M$9.08M
Shares outstanding5.34M2.00M445,9083.33M650,667
Cash flow statement
Operating cash flow-$8.64M-$8.10M-$6.99M-$7.28M-$15.58M
Capital expenditure——$9,293$160,014$39,108
Free cash flow——-$7.00M-$7.44M-$15.62M
Investing cash flow——-$9,293-$661,804-$672,999
Financing cash flow$94,496$12.27M$4.65M$10.68M$15.07M
Depreciation & amortization$205,271$212,839$219,600$202,249$185,657
Stock-based compensation$106,866$119,307$137,714$278,155$697,894

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.